

PRESS RELEASE

Otočec

10 July 2025

Today, Hotel Šport in Otočec is the venue of the 31st regular Annual General Meeting (AGM) of Krka, tovarna zdravil, Novo mesto.

The President of the Management Board and CEO Jože Colarič presented key 2024 Krka Group business results and an estimate of certain operating results for the first half of 2025 and stated: 'Our business performance continued to be good throughout the first half of the year. We increased revenue in five sales regions and most markets. Key business results for the first half of the year have been the best since incorporation. Half-year sales outstripped €1 billion for the first time. We estimated product and service sales growth at 7% and net profit at 11%. All key financial indicators improved year on year as well. The Supervisory Board is scheduled to discuss unaudited operating results of Krka and the Krka Group for the first half of 2025 at their regular meeting of 23 July. A press release is due on the following day. We expect to meet our annual plans by the end of the year, taking into account the performance estimate for the first half of 2025.'

As the AGM unfolded, shareholders voted on proposed resolutions. The information follows in a separate notice.

Krka Group estimated operating results for H1 2025

Financial highlights


€ million	Estimate Jan–Jun 2025	Jan–Jun 2024	Index
Revenue	1,048.5	985.4	106
– Of which revenue from products and services	1,045.8	980.8	107
Earnings before interest, tax, depreciation and amortisation (EBITDA)	303.3	283.7	107
Operating profit (EBIT)	257.0	237.7	108
Net profit	246.7	221.6	111
Ratios			
EBITDA margin	28.9%	28.8%	
EBIT margin	24.5%	24.1%	
Net profit margin (ROS)	23.5%	22.5%	

Sales

Estimated product and service sales by region

€ million	Estimate Jan–Jun 2025	Jan–Jun 2024	Index
Region Slovenia	64.4	59.9	108
Region South-East Europe	148.2	137.4	108
Region East Europe	370.4	332.4	111
Region Central Europe	242.5	227.6	107
Region West Europe	187.0	183.9	102
Region Overseas Markets	33.2	39.6	84
Total	1,045.8	980.8	107

Estimated product and service sales by region in H1 2025



The figures in parentheses show year-on-year changes in sales by region.

The Group's largest region in terms of sales value was Region East Europe, generating €370.4 million in product sales. The Russian Federation, our largest individual market, recorded product sales of €218.6 million, up 12% year on year. Ukraine, our third largest individual market in size, recorded product sales of €49.7 million, up 8% year on year. We generated €31.7 million in product sales in Uzbekistan, up 11%. We also recorded sales growth in all other markets of eastern Europe and central Asia, except in Kazakhstan and Georgia.

Region Central Europe recorded product sales of €242.5 million. Product sales in Poland, our second largest individual market in size, generated €122.0 million in product sales, a 12% year-on-year increase. Product sales amounted to €34.4 million (up 9%) in Czechia, and €28.0 million (down 9%) in Hungary. We recorded sales growth in most other regional markets.

Generating €187.0 million, Region West Europe was the third largest region in terms of sales value. In Germany, the largest regional market and our fourth largest individual market in size, product sales amounted to €46.9 million, up 3% year on year. Our regional sales saw the highest increases in Belgium (up 38%), Austria (up 26%), and the Netherlands (up 20%).

Region South-East Europe generated product sales of €148.2 million. We increased sales in all regional markets. In Romania, product sales totalled €40.3 million, up 5% year on year.


Product and service sales in Region Slovenia totalled €64.4 million. According to the latest available data for the first half of 2025, we retained the leading position among pharmaceutical suppliers, holding a 7.3% share of the Slovenian market.

Region Overseas Markets recorded a drop in sales primarily owing to a sales decrease in the Middle East.

Estimated product and service sales by group

€ million	Estimate Jan–Jun 2025	Jan–Jun 2024	Index
Human health products	956.2	897.1	107
– Prescription pharmaceuticals	878.3	823.4	107
– Non-prescription products	77.9	73.8	106
Animal health products	63.4	60.4	105
Health resort and tourist services	26.2	23.3	112
Total	1,045.8	980.8	107

Estimated product and service sales by group in H1 2025



The figures in parentheses show year-on-year changes in sales by product and service group.

New products

We develop, seek regulatory approvals for, and launch many products on market. We added eleven new products to our portfolio in the first half of 2025, nine prescription pharmaceuticals, one non-prescription product, and one animal health product. We market them under different brand names in individual markets.

We obtained marketing authorisations for three new antidiabetic agents, allowing for contemporary, patient-tailored therapy. Our innovative antidiabetic agent Dagrado (dapagliflozin/sitagliptin) is an innovative single-pill combination in film-coated tablets. The agent combines two distinct mechanisms of action to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and sitagliptin is appropriate. A single-pill combination Mexdagry (dapagliflozin/metformin) in film-coated tablets ensures effective glycaemic control and good patient compliance. Lynxaram (linagliptin) in film-coated tablets is another antidiabetic agent that can be used as monotherapy or in combination with other agents for reliable glycaemic control. The medicine is taken once a day and no dose adjustment is required for patients with renal impairment.

We added new products to the portfolio of cardiovascular agents, our largest therapeutic class of products. Bi-Prenessa (bisoprolol/perindopril) is a single-pill combination of an ACE inhibitor and a selective beta-blocker indicated for the treatment of coronary artery disease and/or chronic heart failure. The synergistic activity of active ingredients allows for effective blood pressure control. We obtained marketing authorisations for a new strength of Co-Amlessa (perindopril/amlodipine/indapamide) tablets, providing new options for patient-tailored therapies. We were also granted marketing authorisations for updated Telassmo (telmisartan/amlodipine) tablets indicated for blood pressure control with essential hypertension as a replacement therapy for telmisartan and amlodipine taken in separate tablets at the same doses. Pixoroso (rosuvastatin/perindopril) film-coated tablets, an innovative single-pill combination, is indicated for the treatment of patients with concomitant arterial hypertension and hyperlipidaemia to achieve target blood pressure levels and lipids by taking one tablet a day.

We were granted marketing authorisations as the first generic manufacturer for Delanxara (dexketoprofen/tramadol) film-coated tablets. This single-pill analgesic combines two active ingredients with distinct mechanisms of actions. Their synergistic and complementary action effectively relieves moderate to severe pain at low doses with few adverse reactions. We were granted marketing authorisations for vonoprazan film-coated tablets in China. This contemporary medicine for the gastrointestinal tract decreases the amount of acid in the stomach, delivering a quick and sustained relief. We also obtained marketing authorisations for our non-prescription product Septabene (benzylamine/cetylpyridinium chloride) lozenges with cola flavour, in certain countries also marketed as Septotele Total. This popular flavouring of natural origin makes lozenges well-liked by adolescents and young adults. The lozenges, however, have retained demonstrated effectiveness in relieving pain and inflammation in the mouth and throat.

We obtained marketing authorisations for European markets for our new animal health product for companion animals, a spot-on solution Dehinexxa (praziquantel/emodepside), in certain markets also available as Dehispot. This dewormer is indicated for the treatment and prevention of mixed parasitic infestations in cats. In certain countries, it has been approved as a non-prescription product, making it more accessible to pet owners.

Investments

According to estimates, the Krka Group allocated €40.9 million to investments in the first half of 2025, of that €29.6 million to the controlling company.

Employees

At the end of June 2025, the Krka Group employed 13,006 people, up 2% year-to-date, of whom 5,379 or 41% of the total Krka Group headcount worked abroad. The proportion of the Krka Group employees with at least university-level qualifications was 47%, and 202 employees held doctoral degrees. Including agency workers, the Krka Group employed 13,047 persons.

Share and shareholders information

At the end of June 2025, Krka had 47,628 shareholders. On 30 June 2025, the Krka share traded at €193.50 on the Ljubljana Stock Exchange, up 39% on year-end 2024, when it traded at €139.00. Market capitalisation, treasury shares included, totalled €6.3 billion as at 30 June 2025.

In the first half of 2025, Krka acquired 145,232 treasury shares and held 2,252,569 treasury shares as at 30 June 2025, accounting for 6.869 % of its share capital.

Krka Group 2025 business objectives

We expect product and service sales to generate over €2 billion. Net profit is planned at €365 million. The total number of employees in Slovenia and abroad is expected to increase by 1%. We plan to allocate €150 million primarily to expand and technologically upgrade production and development capacities and infrastructure.

Press release on the 2025 performance estimates is due on 13 November 2025. We expect to meet our annual plans by the end of the year, taking into account the performance estimates for the first half of 2025.